The proglucagon gene is expressed in both pancreatic A cells and intestinal L cells. Tissue-specific post-translational processing of proglucagon by the prohormone convertase produces the different proglucagon derived peptides (PGDPs) in both pancreas and intestine. The most notable pancreatic PGDP is glucagon, whereas the L cells produce several structurally related peptides, including glucagon-like peptide (GLP)-1 and GLP-2, as well as glicentin and oxyntomodulin, which contain glucagon sequence in their molecules. Among PGDPs, GLP-2 has recently been found to show intestinal epithelial proliferation. GLP-1 has a major effect of enhancing the release of insulin in response to a glucose stimulus, and coincidentally, suppressing secretion of glucagon. GLP-1 has been shown to potently inhibit several aspects of digestive function, including gastric emptying, gastric secretion and pancreatic secretion.

The antibody is stable for at least 1 year from the date of receipt when stored at -20°C to -70°C. Reconstituted antibody can also be aliquotted and stored at 4°C for 1 month or at -20°C to -70°C in a manual defrost freezer for many months without detectable loss activity. Please avoid freeze-thaw cycles.

The rabbit anti-human Glucagon-like peptide-1 antibody detected specifically target derived from human recombinant protein and cellular lysates. Cross reactivity with mouse and rat GLP-1 has not yet been tested.